ZI-KL1-1

N/A

Report date: 2025/02/14 17:42:23

Base Information

Drug NameZI-KL1-1
Drug Alias NameZI-KL1-1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsKita-kyushu lung cancer antigen 1 modulators
TargetsKita-kyushu lung cancer antigen 1
Therapy Area/IndicationsUterine Cervical NeoplasmsLung NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesZelluna Immunotherapy AS
China Registration ClassN/A

Develop Information

Active CompaniesZelluna Immunotherapy AS
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsLung NeoplasmsPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A